Get the best of CNBC in your inbox
Jeffrey Rosenberg, BlackRock's chief investment strategist, shares his thoughts on how to increase returns amid a low-rate environment.
CNBC's Josh Lipton and USA Today San Francisco Bureau Chief Jon Swartz discuss what Apple's acquisition plans say about its hardware business.
What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.
Barry Dawes, Head of Resources at Paradigm Securities, says geopolitics are unlikely to affect oil since prices are being supported by firm underlying demand.
Mikihiko Yamato, Deputy Head of Research at Ji Asia, says monthly comparisons show that June's retail sales are on an uptrend, indicating that consumption is improving
Greg Gibbs, Senior Currency Strategist at RBS, says upcoming U.S. economic data must at least meet expectations in order for the greenback to remain firm.
Ranjith Gopinathan, programme manager, life sciences and healthcare practice at Frost & Sullivan, discusses pharmaceutical groups Merck and Pfizer ahead of their quarterly results.
Hessam Nadji, CSO at Marcus and Millichap, discusses the U.S. real estate market and says that on the residential side, the back half of the year should be "pretty strong".
Dan Greenhaus, chief global strategist at BTIG, says that on a relative basis, the U.S. equity market remains "where you want to be".